NASDAQ:IMRX

Immuneering Stock News

Healthcare > Biotechnology

Buy IMRX

*Your capital is at risk

$4.54

+0.1000 (+2.25%)

At Close: Jun 23, 2026

Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates

06:30am, Thursday, 09'th Sep 2021

Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024

Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

04:07pm, Tuesday, 03'rd Aug 2021

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by